<pre id="9vxtt"><del id="9vxtt"></del></pre>

          <pre id="9vxtt"></pre><pre id="9vxtt"><del id="9vxtt"><dfn id="9vxtt"></dfn></del></pre>
          <pre id="9vxtt"></pre>
          <pre id="9vxtt"><b id="9vxtt"><thead id="9vxtt"></thead></b></pre>

            Pipeline

            Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

            Pipeline

            HIV / AIDS

            Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

            The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

            • Emtricitabine and tenofovir alafenamide

              Potential Indication: PrEP

              Phase 1
              Phase 2
              Phase 3
            • GS-6207 (Capsid Inhibitor)

              Potential Indication: HIV/AIDS

              Phase 1
              Phase 2
              Phase 3
            • Vesatolimod (TLR-7 agonist)

              Potential Indication: HIV/AIDS

              Phase 1
              Phase 2
              Phase 3
            • Elipovimab (bNab)

              Potential Indication: HIV/AIDS

              Phase 1
              Phase 2
              Phase 3

            Liver Diseases

            Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

            The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

            • Cilofexor (FXR agonist)

              Potential Indication: NASH

              Phase 1
              Phase 2
              Phase 3
            • Cilofexor (FXR agonist)

              Potential Indication: Primary Biliary Cirrhosis

              Phase 1
              Phase 2
              Phase 3
            • Cilofexor (FXR agonist)

              Potential Indication: Primary Sclerosing Cholangitis

              Phase 1
              Phase 2
              Phase 3
            • Firsocostat (ACC Inhibitor)

              Potential Indication: NASH

              Phase 1
              Phase 2
              Phase 3
            • Selgantolimod (TLR-8 agonist)

              Potential Indication: HBV

              Phase 1
              Phase 2
              Phase 3
            • GS-4224 (PD-L1 Inhibitor)

              Potential Indication: HBV

              Phase 1
              Phase 2
              Phase 3

            Hematology / Oncology

            Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

            The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

            • Axicabtagene ciloleucel

              Trial: ZUMA-5 Potential Indication: Indolent NHL

              Phase 1
              Phase 2
              Phase 3
            • Axicabtagene ciloleucel

              Trial: ZUMA-6 Potential Indication: DLBCL (+PD-L1 mAb)

              Phase 1
              Phase 2
              Phase 3
            • Axicabtagene ciloleucel

              Trial: ZUMA-7 Potential Indication: 2nd line DLBCL

              Phase 1
              Phase 2
              Phase 3
            • Axicabtagene ciloleucel

              Trial: ZUMA-11, Potential Indication: DLBCL (+4-1BB)

              Phase 1
              Phase 2
              Phase 3
            • Axicabtagene ciloeucel

              Trial: ZUMA-12 Potential Indication: 1st line DLBCL

              Phase 1
              Phase 2
              Phase 3
            • Axicabtagene ciloleucel

              Trial: ZUMA-14 Potential Indication: DLBCL (+rituximab or lenalidomide)

              Phase 1
              Phase 2
              Phase 3
            • KTE-X19

              Trial: ZUMA-2 Potential Indication: MCL

              Phase 1
              Phase 2
              Phase 3
            • KTE-X19

              Trial: ZUMA-3 Potential Indication: Adult ALL

              Phase 1
              Phase 2
              Phase 3
            • KTE-X19

              Trial: ZUMA-4 Potential Indication: Pediatric ALL

              Phase 1
              Phase 2
              Phase 3
            • KTE-X19

              Trial: ZUMA-8 Potential Indication: CLL

              Phase 1
              Phase 2
              Phase 3
            • KITE-718 (MAGE A3/A6)

              Potential Indication: Solid Tumor

              Phase 1
              Phase 2
              Phase 3
            • KITE-439 (HPV E7)

              Potential Indication: Solid Tumor

              Phase 1
              Phase 2
              Phase 3
            • GS-1423 (bi-specific antibody)

              Potential Indication: Solid Tumor

              Phase 1
              Phase 2
              Phase 3
            • GS-4224 (oral PD-L1 inhibitor)

              Potential Indication: Solid Tumor

              Phase 1
              Phase 2
              Phase 3

            Inflammation / Respiratory

            Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

            The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

            • Filgotinib (JAK1 inhibitor)

              Potential Indication: Rheumatoid Arthritis

              Phase 1
              Phase 2
              Phase 3
            • Filgotinib (JAK1 inhibitor)

              Potential Indication: Crohn's Disease

              Phase 1
              Phase 2
              Phase 3
            • Filgotinib (JAK1 inhibitor)

              Potential Indication: Ulcerative Colitis

              Phase 1
              Phase 2
              Phase 3
            • Filgotinib (JAK-1 inhibitor)

              Potential Indication: Psoriatic Arthritis

              Phase 1
              Phase 2
              Phase 3
            • Filgotinib (JAK1 inhibitor)

              Potential Indication: Inflammatory Diseases

              Phase 1
              Phase 2
              Phase 3
            • Filgotinib (JAK-1 inhibitor)

              Potential Indication: Ankylosing Spondylitis

              Phase 1
              Phase 2
              Phase 3
            • GS-9876 (Syk inhibitor)

              Potential Indication: Sjogren’s Syndrome

              Phase 1
              Phase 2
              Phase 3
            • GS-9876 (Syk inhibitor)

              Potential Indication: Lupus

              Phase 1
              Phase 2
              Phase 3
            • GS-4875 (TPL2 inhibitor)

              Potential Indication: Ulcerative Colitis

              Phase 1
              Phase 2
              Phase 3
            • GLPG-1690

              Potential Indication: Idiopathic Pulmonary Fibrosis

              Phase 1
              Phase 2
              Phase 3
            • GLPG-1690

              Potential Indication: Systemic Sclerosis

              Phase 1
              Phase 2
              Phase 3
            • Selonsertib (ASK-1 inhibitor)

              Potential Indication: DKD

              Phase 1
              Phase 2
              Phase 3

            Other

            Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

            The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

            • Remdesivir (GS-5734, Nuc inhibitor)

              Potential Indication: Ebola Virus Infection

              Phase 1
              Phase 2
              Phase 3

            Some of the content on this page is not intended for users outside the US.

            欧美牲交aⅴ人妖